Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease

Authors Mohammed Al-Omran

Published Date January 2007 Volume 2007:3(6) Pages 1019—1027

DOI http://dx.doi.org/

Published 15 January 2007

Mohammed Al-Omran

Department of Surgery, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Background: Peripheral arterial disease (PAD) is a marker of advanced atherosclerosis with an elevated risk of cardiovascular mortality and morbidity. Although intensive risk reduction therapy is critical in reducing the adverse cardiovascular outcomes in patients with PAD, the awareness of this information among all physicians is felt to be low. Given the role of family physicians (FP), general internists (GI), cardiologists (C), and vascular surgeons (VS) in treating patients with PAD, we sought to determine their perceptions and knowledge of risk reduction therapy in these patients.

Methods and results: We conducted a cross-sectional self-administered survey of 84 physicians who work at a major teaching hospital. FP, GI, C, and VS represent 39%, 33%, 16%, and 12% of the surveyed physicians, respectively. The recommended targets of LDL-cholesterol, blood glucose and blood pressure in PAD patients were known to 37.3%, 94.1% and 35.3% of physicians, respectively. The majority of physicians reported to screen for risk factors in PAD. Although 86.3% of physicians would recommend antiplatelets therapy in PAD, only 17.6% would recommend angiotensin converting enzyme (ACE) inhibitors; 25.5% would recommend nicotine replacement therapy for smokers and 62.7% would recommend statins. Compared to other specialties, cardiologists had the lowest threshold, whereas GI had the highest threshold for initiating antiplatelets and statins for patients with PAD.

Conclusion: The perceptions towards risk reduction in PAD identify glaring knowledge and action gaps. Effective strategies to encourage health professionals to use risk reduction therapy are needed.
Keywords: peripheral arterial disease, risk reduction, atherosclerosis

Download Article [PDF] 

Readers of this article also read:

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

The benefits and risks of testosterone replacement therapy: a review

Nazem Bassil, Saad Alkaade, John E Morley

Therapeutics and Clinical Risk Management 2009, 5:427-448

Published Date: 11 June 2009

Tinidazole in the treatment of bacterial vaginosis

Nicola R Armstrong, Janet D Wilson

International Journal of Women's Health 2009, 1:59-65

Published Date: 25 June 2009

Multidrug-resistant Acinetobacter lwoffii infection in neonatal intensive care units

Narongsak Nakwan, Jeerawan Wannaro, Narongwit Nakwan

Research and Reports in Neonatology 2011, 1:1-4

Published Date: 10 January 2011

Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB

Infection and Drug Resistance 2011, 4:97-113

Published Date: 3 May 2011

Moderate alcohol consumption and cognitive risk

Neafsey EJ, Collins MA

Neuropsychiatric Disease and Treatment 2011, 7:465-484

Published Date: 11 August 2011

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Key feasibility considerations when conducting vaccine clinical trials in Asia–Pacific countries

Lansang EZ, Tan K, Nayak S, Lee KJ, Wai K

Vaccine: Development and Therapy 2013, 3:1-9

Published Date: 19 March 2013